Market Narratives
Market themes driving price action · Updated Jul 24, 2026
TSLA price target: bull case 2027
An article belongs to this narrative if it discusses Tesla's price target or bullish case for the year 2027.
Ad agencies settle US FTC probe into political content boycott
An article belongs to this narrative if it discusses antitrust investigations and settlements involving advertising agencies and political content.
CRM oversold conditions
An article belongs to this narrative if it discusses the oversold conditions of Salesforce (CRM) stock.
Trans athletes sports ban
An article belongs to this narrative if it discusses the Supreme Court's ruling on trans athletes in sports.
Wolfe Research initiates 'Peer Perform' rating on Tyra Biosciences
An article belongs to this narrative if it discusses Wolfe Research's rating and price target for Tyra Biosciences.
AMLX awaits key LUCIDITY trial data
An article belongs to this narrative if it discusses Amylyx Pharmaceuticals' LUCIDITY trial data.
Flowco Holdings Becomes Oversold
An article belongs to this narrative if it discusses Flowco Holdings' stock becoming oversold.
Kirby Becomes Oversold
An article belongs to this narrative if it discusses Kirby's stock becoming oversold.
Market Cap Shifts in Utilities
An article belongs to this narrative if it discusses changes in market capitalization among utility companies.
Market cap rank shifts in technology
An article belongs to this narrative if it discusses changes in market capitalization rank among technology companies.
Evommune becomes oversold
An article belongs to this narrative if it discusses Evommune's RSI reading and oversold status.
American Superconductor enters oversold territory
An article belongs to this narrative if it discusses the RSI reading and oversold status of American Superconductor.
Tylenol autism lawsuits revived against Kenvue
An article belongs to this narrative if it discusses the legal proceedings involving Tylenol and autism claims against Kenvue.
E-commerce chargebacks surge due to online fraud
An article belongs to this narrative if it discusses the increase in credit card chargebacks due to online fraud and confusing billing practices in e-commerce.
US energy efficiency progress and trends
An article belongs to this narrative if it discusses the historical and current trends in US energy efficiency.
BlackRock International Growth and Income Trust breaks below 200-day moving average
An article belongs to this narrative if it discusses BlackRock International Growth and Income Trust crossing below its 200-day moving average.
RH shares cross below 200-day moving average
An article belongs to this narrative if it discusses RH shares crossing below their 200-day moving average.
CRY becomes very oversold
An article belongs to this narrative if it discusses CRY's RSI reading and oversold status.
Takeda Pharmaceutical's LATITUDE Atlas Study Success
An article belongs to this narrative if it discusses Takeda Pharmaceutical's success in the LATITUDE Atlas study.
Xeris Biopharma's Extended Keveyis Exclusivity
An article belongs to this narrative if it discusses Xeris Biopharma's extended exclusivity for Keveyis.
BIOA initiates Phase 2 cardiovascular study
An article belongs to this narrative if it discusses BioAge Labs' Phase 2 cardiovascular study.
Pharma stocks at risk from Medicare drug price negotiation updates
An article belongs to this narrative if it discusses proposed changes to Medicare D drug price negotiations affecting multiple pharma stocks.
AKBA strengthens Vafseo patent protection
An article belongs to this narrative if it discusses Akebia Therapeutics' patent protection for Vafseo.
SNDX price target revised amid AML market estimates
An article belongs to this narrative if it discusses Syndax Pharmaceuticals' price target revision due to AML market estimates.